According to the Code of Public Health, the pharmacist advises and informs the patient to ensure the right use and high drug adherence. In Clinical Trials (CT), Investigational Medicinal Products (IMP) are dispensed by pharmacy department.

A copy of the prescription is given to the patients in ambulatory: it’s a support of information for the patient available at any time at home. In our hospital, prescriptions for CT are usually provided by the sponsor.

The purpose of this work is to evaluate information about IMP on the prescriptions provided by the sponsors and to propose areas for improvement.

All the CTs with at least one IMP was taken at home and opened in the pharmacy department of a university hospital on 1 January 2018 were included in this retrospective study. A check list of 8 criteria deemed essential to inform the patient regarding his treatment was created in accordance with the regulations.

The most frequent information on prescriptions is the dosage and the packaging of the IMP. At the other end, information on what to do in case of adverse event and drug interactions are rare or non-existent. The pharmacist has an important and essential role to dispense pharmaceutical advice for CT (1). A collaboration between services and pharmacy is planned in order to establish a standard prescription for CTs with specific information. Improving the quality of prescription information will optimize the safety of IMP taking.

(1) J.A. Schoenenberger et al. Assessment of the information on investigational oral treatment provided to patients in clinical trials. European Journal of Hospital Pharmacy 2012, 19 (2)230-231.